SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS

Dec 8, 2020

For Immediate Release December 8, 2020

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC PINK:  “SBFM”), a pharmaceutical company focused on the research, development and  commercialization of oncology and antiviral drugs, today announced that it has ordered a new  batch of Adva-27a from its manufacturer in China. The material will be delivered to the  laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). 

Sunshine plans to use the material to conduct testing on various types of cancer cells that  overproduce Topoisomerase II (TopII). Following these cell culture studies, Sunshine will  proceed to performing studies on mice harboring tumors of human origin with TopII  amplification. TopII is an essential cell cycle enzyme that is amplified in approximately 4% of all  human cancers. 

“All cancer types that have amplification of the Topoisomerase II gene are potential new targets  for our Adva-27a,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “This is an additional application for our Adva-27a beyond the original multidrug resistance indication,” he added. 

About Sunshine Biopharma 

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is  engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to  date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant  Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer  cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to  be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine  Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. 

Safe Harbor Forward-Looking Statements 

This press release may contain forward looking statements which are based on current expectations, forecasts, and  assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ  materially from those anticipated or expected, including statements related to the amount and timing of expected  revenues statements related to our financial performance, expected income, distributions, and future growth for  upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by  the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain 

events could differ materially from those projected in or contemplated by the forward-looking statements due to a  number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not  be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock  market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC  filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as  new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the  near and long term. Additional service offerings may expose us to additional legal and regulatory costs and  unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of  which cannot be predicted at this time. 

For Additional Information Contact: 

Camille Sebaaly, CFO 

Sunshine Biopharma Inc. 

Direct Line: 514-814-0464 

camille.sebaaly@sunshinebiopharma.com 

www.sunshinebiopharma.com